The deal isn’t done, but would be Merck’s biggest oncology buy.
ApexOnco Front Page
Recent articles
Padcev still looks good in first-line bladder, but Pfizer hopes to make a mark in muscle-invasive disease.
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
AstraZeneca bags three of the month’s four oncology approvals.
Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.
Firce-1 is scrapped after showing dismal response rates and patient deaths.
On a wing and a prayer Leap heads for phase 3.
Meanwhile, Olema’s KAT6 inhibitor will take on rival projects from Pfizer and Menarini.
